LMWH vs Aspirin for VTE Prophylaxis in Orthopaedic Oncology
At a glance
Conditions
NCT03244020
Where you'd take part
This study runs at 10 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
Beth Israel Deaconess Medical Center
Boston, Massachusettsno site contact published
Brigham and Women's Hospital
Boston, Massachusettsno site contact published
Cleveland Clinic
Cleveland, Ohiono site contact published
Cooper University Health Care
Camden, New Jerseyno site contact published
Johns Hopkins University
Baltimore, Marylandno site contact published
Louisiana State University Health
New Orleans, Louisianano site contact published
Moffitt Cancer Center
Tampa, Floridano site contact published
Santiago Lozano-Calderon
Boston, Massachusettsno site contact published
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- Santiago A Lozano-Calderon, MD, PhD · PRINCIPAL_INVESTIGATOR · Massachusetts General Hospital
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
What this trial measures
- Venous thromboembolismUp to 3 or 6 months post operatively for bone/soft tissue sarcomas and metastatic osseous disease, respectively
Deep venous thrombosis; pulmonary embolus